1女性系统性红斑狼疮患者的抗dsDNA滴度与疾病表现，损伤和抗磷脂抗体的关系-西京风湿免疫

翻译者：杨西超，西京医院临床免疫科
研究背景
目前正在尝试揭开关于抗双链脱氧核糖核酸（anti-dsDNA）的未解决疑问，抗dsDNA的确致病作用以及阻断它们的程度将是一个潜在的治疗目标穆塔西姆。
研究目的
本研究的目的是确定系统性红斑狼疮（SLE）患者的抗dsDNA抗体滴度神魔系统 ，并研究其与疾病特征，活性，损伤和抗磷脂自身抗体（aPL）的关系。
研究方法
纳入70例女性SLE患者和35例年龄和性别匹配的对照者。测量抗dsDNA水平和aPL。评估系统性红斑狼疮疾病活动指数（SLEDAI）和系统性狼疮国际协作组/美国风湿病学会损伤指数（SLICC / ACR-DI）仙铃。
研究结果
患者平均年龄27.5±5.1岁，病程7.7±5.4年，高兮妍 SLEDAI和SLICC / ACR-DI评分分别为6.8±8.04和1.2±1.3。在61.4％的患者中抗dsDNA阳性，滴度（133.2±100.5IU / ml）显着高于对照（22.03±17.2IU / ml）（p u003c0.0001）。在具有肌肉骨骼表现（p = 0.007）和阳性抗β2糖蛋白（抗-β2GP）（p = 0.037）的患者中抗dsDNA水平显着增加并且在患有神经精神表现的患者（p = 0.004）和接受环磷酰胺（CYC）（p = 0.013）。病情活动患者的抗dsDNA水平往往较高。抗dsDNA滴度与红细胞沉降率（p = 0.001）如果这是爱 ，抗心磷脂IgG和IgA抗体（p = 0.008）和抗β2GPIgG（p = 0.03）和IgA（p = 0.002）显著相关，与总的白细胞计数（p u003c0.0001）和SLICC / ACR-DI（p = 0.001）。
研究结论
SLE患者特别是有肌肉骨骼表现和aPL患者的抗dsDNA水平明显升高。神经精神表现和那些接受CYC的患者似乎可能具有保护作用，并可能形成对疾病组织损伤的屏障。
参考文献：anti-dsDNA titre in female systemic lupus erythematosus patients:relation to disease manifestations,damage and antiphospholipd antibodies
AbstractBackground Attempts are ongoing to unveil unresolved queries about anti-double-stranded deoxyribonucleic acid (anti-dsDNA), their precise pathogenic effects and to what extent blocking them would be a useful therapeutic goal. Objectives The aim of the present study was to determine the anti-dsDNA antibodies titre in systemic lupus erythematosus (SLE) patients and investigate their relation to the disease characteristics, activity, damage and antiphospholipid autoantibodies (aPL). Methods Seventy female SLE patients and 35 age- and sex-matched controls were included. The anti-dsDNA level and aPL were measured. Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and Systemic Lupus International Collaborative Clinics/American College of Rheumatology Damage Index (SLICC/ACR-DI) were assessed. Results The mean age of the patients was 27.5?±?5.1 years, disease duration 7.7?±?5.4 years高乃则 , and SLEDAI and SLICC/ACR-DI scores were 6.8?±?8.04 and 1.2?±?1.3, respectively. Anti-dsDNA was positive in 61.4% of the patients and the titre (133.2?±烽禾影城 ?100.5?IU/ml) was significantly higher compared to controls (22.03邓讴歌 ?±?17.2?IU/ml) ( p?<?0.0001). The anti-dsDNA level was significantly increased in those with musculoskeletal manifestations ( p?=?0.007) and positive anti-β2 glycoprotein (anti-β2GP) ( p?=?0.037) and decreased in those with neuropsychiatric manifestations ( p?=?0.004) and those receiving cyclophosphamide (CYC) ( p添翼圈 ?=?0.013). The anti-dsDNA level tended to be higher in active patients. The anti-dsDNA titre significantly correlated with the erythrocyte sedimentation rate ( p?=?0.001), anticardiolipin IgG and IgA antibodies ( p?=?0.008) and anti-β2GP IgG ( p?=?0.03) and IgA ( p神警奇偷?=?0.002) and inversely with the total leucocytic count ( p?<?0.0001) and SLICC/ACR-DI ( p?=?0.001). Conclusion Anti-dsDNA is remarkably increased in SLE patients especially those with musculoskeletal manifestations and aPL. A protective role seems likely in those with neuropsychiatric manifestations and those receiving CYC and may form a shield against disease tissue damage.